Abstracts tagged "clinical trial"

Abstract Number: 1015 • ACR Convergence 2022
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Alexander Egeberg¹, William Tillett², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Understanding factors that impact response to therapy may help improve disease management, clinical outcomes and patient quality of life. Nails are often overlooked in…
Abstract Number: 1531 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
Yannick Allanore¹, Madelon Vonk², Oliver Distler³, Arata Azuma⁴, Maureen Mayes⁵, Alexandra James⁶, Veronika Kohlbrenner⁷, Margarida Alves⁸, Dinesh Khanna⁹ and Kristin Highland¹⁰, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH
Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…
Abstract Number: 1808 • ACR Convergence 2022
Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients with Inter-critical Gout
Swamy Venuturupalli¹, Ami Ben-artzi², Tasmia Amjad³, Amit Kumar⁴, Nikhil Davuluri³, Timothy Chu³, Umair Khan³, Diego Parra³, Natalie Fortune³ and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ³Attune Health, Beverly Hills, CA, ⁴Attune Health, Beverly Hils, CA
Background/Purpose: Percutaneous ultrasound-guided needle synovial biopsies can now be performed at the bedside. To date, no synovial biopsy studies have been conducted in gout patients.…
Abstract Number: 1996 • ACR Convergence 2022
Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis
Lotte van Ouwerkerk¹, Patrick Verschueren², Pascal de Jong³, Paul Emery⁴, Josef Smolen⁵, Robert Landewé⁶, Willem Lems⁷, Maarten Boers⁸, Tom Huizinga¹, CF Allaart¹ and Sytske Anne Bergstra⁹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospital Leuven, Leuven, Belgium, ³ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Medical University of Vienna, Vienna, Austria, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹LUMC, Leiden, Netherlands
Background/Purpose: Short-term (< 3 months) treatment with glucocorticoids (GC) ("bridging") is recommended in the EULAR 2019 rheumatoid arthritis (RA) recommendations when starting a csDMARD in…
Abstract Number: 2117 • ACR Convergence 2022
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
Philip J Mease¹, Laura Coates², Robert Landewé³, Iain B McInnes⁴, Christopher Ritchlin⁵, Tatsuya Atsumi⁶, Frank Behrens⁷, Dafna Gladman⁸, Laure Gossec⁹, Peter Nash¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Jason Coarse¹², Adam R Prickett¹³ and Alice Gottlieb¹⁴, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Amsterdam University Medical Center, Meerssen, Netherlands, ⁴Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Hokkaido University, Sapporo, Japan, ⁷Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁸Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁹Sorbonne Université, Paris, France, ¹⁰School of Medicine, Griffith University, Sunshine Coast, Australia, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹³UCB Pharma, Brussels, Belgium, ¹⁴Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a disease with multiple manifestations; it is important that the efficacy of new interventions is assessed by composite endpoints across…
Abstract Number: 0001 • ACR Convergence 2022
12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)
John Botson¹, kenneth saag², Jeff Peterson³, Katie Obermeyer⁴, Brian LaMoreaux⁴, Suneet Grewal⁵, Amar Majjhoo⁶, John Tesser⁷ and Michael Weinblatt⁸, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²University of Alabama at Birmingham, Birmingham, AL, ³Western Washington Arthritis Clinic, Seattle, WA, ⁴Horizon Therapeutics plc, Deerfield, IL, ⁵East Bay Rheumatology Medical Group, Inc., San Leandro, CA, ⁶Shores Rheumatology, PC, Troy, MI, ⁷Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The MIRROR RCT trial examined pegloticase (PEGylated uricase) safety and efficacy with methotrexate (MTX) vs placebo (PBO) as co-therapy. Sustained urate-lowering rate during Month…
Abstract Number: 0297 • ACR Convergence 2022
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Adriana Kakehasi², Neil Basu³, David A. Walsh⁴, Andra Balanescu⁵, Clifton Bingham⁶, Andrew Garrison⁷, Ivan Lagunes⁸, sander strengholt⁹, Ralph Lippe¹⁰ and Maxime Dougados¹¹, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴University of Nottingham, Nottingham, United Kingdom, ⁵University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ⁶Johns Hopkins University, Baltimore, MD, ⁷AbbVie, Inc., North Chicago, IL, ⁸AbbVie, Inc., Mettawa, IL, ⁹AbbVie, Inc., Abcoude, Netherlands, ¹⁰AbbVie, Inc, Wiesbaden, Germany, ¹¹Université de Paris, Paris, France
Background/Purpose: Residual pain remains a challenge that prevents patients (pts) with RA from achieving a better quality of life. Current RA treatments have demonstrated efficacy…
Abstract Number: 0391 • ACR Convergence 2022
Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
William Tillett¹, Alexander Egeberg², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Nail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed…
Abstract Number: 0746 • ACR Convergence 2022
Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial
Ho SO¹, Evelyn Chow², Isaac Cheng¹, Xerox Lau², Tena Li¹, Cheuk Chun Szeto² and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit…
Abstract Number: 1035 • ACR Convergence 2022
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
Philip J Mease¹, William Tillett², Sarah Ohrndorf³, Michelle Perate⁴, Mary Medysky⁵, Miriam Zimmermann⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Paul Bird⁹, Alen Zabotti¹⁰, Atul Deodhar¹¹ and Dafna Gladman¹², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Seattle, WA, ⁶Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹University of New South Wales, Sydney, Australia, ¹⁰Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ¹²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…
Abstract Number: 1536 • ACR Convergence 2022
Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR
Anna-Maria Hoffmann-Vold¹, Cathrine Brunborg¹, Paolo Airò², Lidia P. Ananyeva³, László Czirják⁴, Serena Guiducci⁵, Eric Hachulla⁶, MENGTAO LI⁷, Carina Mihai⁸, Gabriela Riemekasten⁹, Petros P. Sfikakis¹⁰, Gabriele Valentini¹¹, Otylia Kowal-Bielecka¹², Yannick Allanore¹³ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ³V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁴Medical school of Pécs, Pecs, Hungary, ⁵University of Firenze, Firenze, Italy, ⁶University of Lille, Lille, France, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁹University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁰Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ¹¹Università della Campania “Luigi Vanvitelli”, Napoli, Italy, ¹²Medical University of Bialystok, Bialystok, Poland, ¹³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: Short disease duration is a well known predictor for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD), but studies assessing ILD progression in later disease…
Abstract Number: 1829 • ACR Convergence 2022
Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
Lindsay Helget¹, Anne Davis-Karim², James O'Dell¹, Ted Mikuls³, Jeff Newcomb¹, Maria Androsenko⁴, Mary Brophy⁴, Bryant England¹, Ryan Ferguson⁴, Michael Pillinger⁵, Tuhina Neogi⁶, Hongsheng Wu⁴ and Paul Palevsky⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Boston University School of Medicine, Boston, MA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone in the treatment of gout, which afflicts over 2 million individuals with chronic kidney disease (CKD) in…
Abstract Number: 1997 • ACR Convergence 2022
Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
Rebecca Blank¹, Alba Boix-Amoros², Renuka Nayak³, Anthony Jimenez Hernandez¹, Sydney Catron⁴, Zakwan Uddin⁴, Erin Reilly⁵, Andrew Patterson⁵, Peter Turnbaugh⁶, Jose Clemente² and Jose Scher⁷, ¹NYU School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴NYU Langone Health, New York, NY, ⁵Pennsylvania State University, College Park, PA, ⁶UCSF, San Francisco, ⁷New York University School of Medicine, New York, NY
Background/Purpose: The gut microbiome and its metabolites are dysregulated in rheumatoid arthritis. Short chain fatty acids (SCFAs), microbial fermentation byproducts of certain gut microbes, induce…
Abstract Number: 2137 • ACR Convergence 2022
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
Lihi Eder¹, Laura Coates², Peter Nash³, Uta Kiltz⁴, Ennio Lubrano⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁷ and Alexis Ogdie⁸, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…
Abstract Number: 0003 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
Toby Maher¹, Veronica Tudor², Peter Saunders³, Michael Gibbons⁴, Sophie Fletcher⁵, Helen Parfrey⁶, Chris Denton⁷, Rachel Hoyles³, Elizabeth Renzoni², Maria Kokosi², Athol Wells², Deborah Ashby⁸, Matyas Szigeti⁸ and Philip Molyneaux⁸, ¹University of Southern California, Los Angeles, CA, ²Royal Brompton Hospital, London, United Kingdom, ³Oxford University Hospitals, Oxford, United Kingdom, ⁴Royal Devon and Exeter Hospital, Exeter, United Kingdom, ⁵Southampton University Hospitals, Southampton, United Kingdom, ⁶Addenbrookes Hospital, Cambridge, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Imperial College London, London, United Kingdom
Background/Purpose: The RECITAL trial (NCT01862926) compared rituximab to cyclophosphamide as first line therapy for patients with severe or progressive interstitial lung disease due to idiopathic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].